An Open Label Phase II Study Combining Nivolumab and Celecoxib in Patients With Advanced " Cold " Solid Tumors

NCT03864575 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

68

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Cancer

Interventions

DRUG: Celecoxib 400 mg

Sponsor

Cliniques universitaires Saint-Luc- Université Catholique de Louvain